Amlexanox

Research-Grade

Amlexanox is not a peptide in the strict structural sense — it is a small molecule (aminoalkylbenzopyranone) that has found significant attention in the peptide and metabolic research community due to its unique mechanism of action on the IKKε/TBK1 kinase axis, a pathway increasingly linked to obesity-driven metabolic dysfunction. Originally approved as a topical treatment for aphthous ulcers (canker sores), amlexanox was repurposed when Alan Bhatt's group at the University of Michigan discovered that genetic deletion of IKKε in mice prevented diet-induced obesity and insulin resistance. Amlexanox, as an IKKε/TBK1 dual inhibitor, recapitulated these genetic findings pharmacologically: treated obese mice showed improved insulin sensitivity, increased energy expenditure, and reduced hepatic steatosis without caloric restriction. A Phase 2 human trial (NCT01975935) showed modest but significant improvements in HbA1c and fasting glucose in type 2 diabetic patients. The peptide research community has adopted amlexanox as a metabolic adjunct alongside GLP-1 agonists and other body composition agents.